Poliomyelitis

chronic diastolic congestive heart failure :: Article Creator Why Congestive Heart Failure And Kidney Disease Often Occur Together When the heart can no longer pump blood efficiently throughout the body, kidney function issues are among the first complications to develop. Congestive heart failure (CHF), a condition that reflects a weakened heart muscle and reduced circulation, can lead to kidney disease and other serious health complications. Kidney disease can also cause circulation problems and force the heart to pump harder, raising the risk of CHF. CHF and kidney disease can be treated with medications and lifestyle adjustments. However, severe heart failure often needs more invasive treatment, and chronic kidney disease may ultimately require dialysis or a kidney transplant. Working closely with your healthcare team to manage these two health challenges will give you the best chance of a positive outcome and a longer life....

prostacyclin pulmonary hypertension :: Article Creator Stanford University Secures NIH Grant To Advance Tiakis Biotech´s Elafin (Tiprelestat) Through A U.S. Phase II Trial In Pulmonary Arterial Hypertension - Novel, disease-modifying treatment option for Pulmonary Arterial Hypertension (PAH), an orphan indication with a significant unmet medical need Kiel, GERMANY, September 8, 2025 – tiakis Biotech AG ("tiakis"), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that its long-standing collaboration partner Stanford University has been awarded a US$ double-digit million grant from the National Institutes of Health (NIH) - National Heart Lung and Blood Institute (NHLBI) - the Lung Division, to fund a U.S. Phase II trial of Tiprelestat for the treatment of Pulmonary Arterial Hypertension (PAH). In early 2025, the U.S. FDA has issued positive ...

cteph :: Article Creator Temple Health's Heart And Vascular Institute Reaches Specialty Milestone Philadelphia-based Temple University Hospital has achieved twin milestones in the treatment of chronic thromboembolic pulmonary hypertension. Care teams from the Advanced Pulmonary Hypertension, Right Heart Failure and CTEPH program at Temple's Heart and Vascular Institute have completed their 500th pulmonary thromboendarterectomy and 500th balloon pulmonary angioplasty. Temple University Hospital is home to the largest CTEPH center in the eastern U.S., with pulmonary thromboendarterectomies only performed at a handful of hospitals across the nation, according to an Aug. 21 news release from the health system. CTEPH is a potentially fatal form of high blood pressure "in the circulation of the lungs resulting from a blood vessel that has been blocked by a prior pulmonary embolism," the release said.  Pulmonary thromboendarterectom...

dr shukla pulmonologist :: Article Creator

over inflated lungs :: Article Creator Cannabis And Tobacco Harm The Lungs Differently, Study Finds A new study from the University of Otago in New Zealand has found that both cannabis and tobacco smoking harm the lungs, but they do so in different ways. This research is being called groundbreaking, especially as cannabis use becomes more common around the world. Professor Bob Hancox, one of the study's authors, explained that long-term cannabis use leads to over-inflated lungs and higher resistance to airflow—more so than tobacco smoking. Cannabis also reduces the lungs' ability to absorb oxygen, which was once believed to be a problem only linked to tobacco. The study used data from the Dunedin Multidisciplinary Health and Development Study, which followed more than 1,000 people born in Dunedin in 1972/73. These individuals were tracked up to age 45, making this one of the most complete studies of lifetime cannabis use and lung f...

systolic dysfunction symptoms :: Article Creator Why Are There So Many Recommendations For Treatment Of Systolic Heart ... Dr. Barry Borlaug answers the question: 'Systolic, Diastolic Disparities?' ByABC News November 20, 2008, 12:04 PM — -- Question: Why are there so many recommendations for the treatment of systolic heart failure and so few for diastolic heart failure management? Answer: Well, I think the main reason is the wealth of clinical trial data that's has been derived from thousands and thousands of patients who've been enrolled in trials of systolic heart failure -- a very clear cut and definitive answers for what works and what doesn't in this patient population. The number is much smaller for diastolic heart failure and the agents which work very well for systolic failure have had more equivocal borderline results in the diastolic population. The other key reason lies in our ...

pulmonary hypertension autoimmune :: Article Creator Pulmovant Receives Orphan Drug Designation In Japan For Mosliciguat For The Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Orphan drug designation from Japan's Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative A global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the European Respiratory Society International Congress 2025 on September 28th WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that Japan's Ministry of Health, Labou...